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Original Research Paper
Effect of dimethyl fumarate on lymphocyte subsets
in patients with relapsing multiple sclerosis
Guy Buckle, Daniel Bandari, Jeffrey Greenstein, Mark Gudesblatt, Bhupendra Khatri, Mariko Kita,
Pavle Repovic, Emily Riser, Bianca Weinstock-Guttman, Ben Thrower, Sherrill Loring,
Katherine Riester, Nick Everage, Claudia Prada, Irene Koulinska and Monica Mann
Abstract
Background: In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically
occurs during the first year and then plateaus; early drops have been associated with the development of
severe prolonged lymphopenia.
Objective: We investigated the effect of dimethyl fumarate on absolute lymphocyte counts and CD4þ/
CD8þ T cells in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate in
routine practice.
Methods: Lymphocyte data were collected via medical chart abstraction. Primary endpoint: change
from baseline in absolute lymphocyte count and CD4þ/CD8þ counts at 6-month intervals following
dimethyl fumarate initiation.
Results: Charts of 483 patients were abstracted and 476 patients included in the analysis. Mean baseline
absolute lymphocyte count (2.23 109/l) decreased by 39% (95% confidence interval: –41.1 to –37.2)
by month 6 and 44% (95% confidence interval: –46.6 to –42.1) by month 12. CD4þ and CD8þ T-cell
subsets strongly correlated with absolute lymphocyte count, with greater decreases from baseline to 6
months vs 6–12 months, and in CD8þ vs CD4þ T cells. Prior natalizumab was not a risk factor for
lymphopenia.
Conclusion: Dimethyl fumarate-associated decline in absolute lymphocyte count in the first 12 months
correlated with decline in CD4þ and CD8þ T cells and was independent of prior natalizumab. Absolute
lymphocyte count monitoring continues to be an effective strategy to identify patients at risk of pro-
longed lymphopenia.
Keywords: Multiple sclerosis, dimethyl fumarate, absolute lymphocyte count, T-cell subsets,
natalizumab
Date received: 14 November 2019; Revised received: 24 January 2020; accepted: 4 February 2020
Introduction
Delayed-release dimethyl fumarate (DMF) is
approved for patients with relapsing–remitting mul-
tiple sclerosis (RRMS).1 As of January 31, 2020,
>445,000 patients have been treated with DMF, rep-
resenting >875,000 patient-years of exposure. Of
these, 6,335 patients (14,241 patient-years) were
from clinical trials. In patients treated with DMF,
absolute lymphocyte count (ALC) decline typically
occurs during the first year and then plateaus.2 Early
drops in ALC are not indicative of clinical
response2–4 but have been associated with
subsequent development of severe prolonged
lymphopenia.2
The main objective of this study was to evaluate
changes in ALC and CD4þ/CD8þ T-cell subtypes
in patients with RRMS receiving DMF in routine
practice. A third of patients enrolled previously
received natalizumab (NAT); NAT’s mechanism of
action typically leads to an increase in ALC, so we
investigated the impact of prior NAT treatment on
ALC and CD4þ/CD8þ T-cell counts. We also
investigated the impact of age (50 vs >50 years)
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on DMF-associated changes in ALC and CD4þ/
CD8þ cell count, given that immunosenescence
may lead to lymphopenia.
Materials and methods
Study design
REALIZE (NCT02519413) was a retrospective,
observational study conducted at nine sites in the
USA, collecting data via medical chart abstraction
at a single timepoint.
Patients and exclusion/inclusion criteria
Eligible patients initiated DMF treatment on/after 27
March 2013 and received 6 months’ continuous
DMF treatment. Other inclusion criteria: aged 18
years; diagnosis of relapsing multiple sclerosis
(MS); measurement for ALC, CD4þ count, and
CD8þ count at baseline; and 1 subsequent time-
point while receiving DMF for 6 months. Key
exclusion criteria: diagnosis of human immunodefi-
ciency virus/acquired immunodeficiency syndrome
and participation in DMF phase 3 studies.3,4
Endpoints
The primary endpoint was estimated adjusted
change from baseline in ALC, CD4þ count, and
CD8þ count at 6-month intervals within 12
months of DMF initiation. Secondary endpoints
assessed at 6 and 12 months following DMF initia-
tion were absolute counts; change from baseline and
percentage change from baseline for lymphocytes
and CD4þ:CD8þ ratio; time to predetermined lym-
phocyte counts; and potential predictors of low lym-
phocyte counts.
Exploratory endpoints included ALC, CD4þ and
CD8þ counts, and CD4þ: CD8þ ratio; incidence
of opportunistic and serious infections; reasons for
DMF discontinuation; and average time to recovery
to baseline values among patients with ALC, CD4þ
count, or CD8þ count less than baseline count, and
less than the lower limit of normal (LLN) after DMF
cessation.
Safety endpoints
Data on serious and opportunistic infections were
captured by the healthcare provider or designated
personnel performing chart abstraction. For opportu-
nistic infections, a list of potential opportunistic
infections was provided or direction was given
remotely. For serious infections, instructions were
given to sites to review the medical record and
capture the infection if it was noted as serious (e.g.
requiring extensive treatment or denoted as severe).
The study management and pharmacovigilance
teams reviewed infection data and queried any infor-
mation necessary for proper assessment of type of
infection.
Statistical analysis
Primary and secondary endpoint analyses were per-
formed on the full analysis population, including all
eligible enrolled patients with an approved waiver of
informed consent. For the primary analysis of ALC,
CD4þ count, and CD8þ count, the change from
baseline at months 6 and 12 was estimated using a
repeated-measures mixed-effects model (RMMM);
model covariates included baseline ALC, study day
(log transformed), and baseline value by study day
interaction. Study day was included as a random
effect. Percentage change from baseline was estimat-
ed at months 6 and 12, as prespecified, and at 15
months after DMF initiation.
For secondary endpoint analysis, absolute counts,
change from baseline, and percentage change from
baseline to months 6 and 12 were summarized for
total lymphocytes, CD4þ and CD8þ cells, and
CD4þ: CD8þ ratio. Assessments were only includ-
ed in the 6 and 12 month tabulation if they were
obtained 30 days from the target timepoint (180
days from DMF initiation for month 6, 360 days
from DMF initiation for month 12).
Logistic regression assessed whether age at baseline
(50 vs >50 years), baseline ALC, and study site
were associated with lymphopenia at months 6 and
12. Association between baseline predictors, per-
centage change, and absolute change from baseline
ALC at months 6 and 12 was assessed by an analysis
of covariance model (rank-transformed).
Post-hoc analyses explored trends in patients with/
without prior NAT exposure, defined as NAT infu-
sion within 180 days of DMF initiation. Using a
RMMM specified for the primary analysis, ALC
changes were estimated for patients with/without
prior NAT exposure. Kaplan-Meier analyses of
time to ALC <0.8 109/l or <0.5 109/l were con-
ducted by prior NAT exposure in patients with a
baseline ALC of 0.8 109/l (n¼ 459) or 0.5
109/l (n¼ 468), respectively. The Cox proportional
hazards model assessed whether prior NAT exposure
was associated with an increased risk of low ALC
(<0.8 109/l or <0.5 109/l), adjusting for age at
DMF initiation and baseline ALC.
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The Pearson correlation statistic assessed association
between ALC and CD4þ/CD8þ counts by age (50
vs >50 years).
Safety analysis
Safety data analyses summarized the incidence of
serious and opportunistic infections using descrip-
tive statistics.
Results
Patient demographics
In total, 483 patient charts were abstracted; 476
patients were included in the full analysis population
(Table 1). Seven patients were excluded post-hoc:
five owing to missing data on DMF discontinuation,
and two owing to inconsistencies in reported labora-
tory values. Most patients were female (73%) and
white (73%). On average, patients were aged 49
years, almost a decade older than patients in pivotal
trials.3,4 Of 476 patients with 1 treatment period
value, 475, 291, 233, and 173 patients had an
assessment 6, 12, >15, and 18 months, respec-
tively, after DMF initiation.
Estimated change in ALC, CD4þ count, and CD8þ
count from baseline
Estimated means for ALC, CD4þ count, and CD8þ
count declined over the study following DMF initi-
ation from baseline to months 6 and 12. The largest
declines were observed during the first 6 months,
with slower rates of decline through month 15.
Mean baseline ALC (2.23109/l) decreased by
39% (95% confidence interval (CI): –41.1 to
–37.2) by month 6 and 44% (95% CI: –46.6 to
–42.1) by month 12 (Table 2). Mean baseline
CD4þ count (1.06109/l) decreased by 37%
(95% CI: –39.3 to –35.1) by month 6 and 42%
(95% CI: –44.5 to –39.8) by month 12. Mean base-
line CD8þ count (0.50109/l) decreased by 47%
(95% CI: –49.0 to –44.1) by month 6 and 53%
(95% CI: –55.5 to –49.9) by month 12 (Table 2).
Table 1. Patient baseline demographics.
Characteristic
Total patients
(n¼ 476)
Patients with
prior NAT exposure
(n¼ 132)
Patients without
prior NAT exposure
(n¼ 344)
Female, n (%) 349 (73) 92 (70) 257 (75)
Age, mean (SD), years 49 (11.0) 50.2 (10.6) 48.4 (11.4)
18–29, n (%) 17 (4) 2 (2) 15 (4)
30–39, n (%) 91 (19) 23 (17) 68 (20)
40–49, n (%) 135 (28) 39 (30) 96 (28)
50–59, n (%) 149 (31) 42 (32) 107 (31)
60, n (%) 84 (18) 26 (20) 58 (17)
Race, n (%)
White 346 (73) 104 (79) 242 (70)
Black or African American 35 (7) 16 (12) 19 (6)
Other 21 (4) 6 (5) 15 (4)
Not reported owing to confidentiality 74 (16) 6 (5) 68 (20)
Prior MS treatment, n (%) 344 (72) 132 (100) 212 (62)
Prior MS treatment type, n (%)
NATa 138 (29) 132 (100) 6 (2)
Glatiramer acetate 66 (14) 4 (3) 62 (18)
Methylprednisolone 60 (13) 18 (14) 42 (12)
Interferon 83 (17) 3 (2) 80 (23)
Methylprednisolone sodium succinate 27 (6) 2 (2) 25 (7)
Teriflunomide 13 (3) 1 (<1) 12 (3)
Fingolimod 13 (3) 0 13 (4)
Other 31 (7) 3 (2) 28 (8)
MS: multiple sclerosis; NAT: natalizumab; SD: standard deviation.
aPrior MS treatment included at any treatment prior to initiating dimethyl fumarate; patients were categorized as “prior
NAT” or “no prior NAT” based on NAT exposure within 6 months of initiating dimethyl fumarate.
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Changes in ALC, and CD4þ/CD8þ T-cell subsets
assessed using raw data, were consistent with esti-
mates from the RMMM (Figure 1(a)–(c)). ALC pos-
itively correlated with CD4þ and CD8þ at baseline
and at months 9–15 in both younger (50) and older
(>50) patients (r>0.744 for all correlations,
p<0.0001). Patients with low ALC also had low
CD4þ and CD8þ counts. Among 46 patients with
the lowest post-baseline ALC of <0.5 109/
l during treatment, all had the lowest post-baseline
CD4þ and CD8þ counts of <0.4 109/l and
<0.2 109/l, respectively.
Prior NAT exposure
Approximately one-third of the patient population
were previously treated with NAT. Mean age was
similar in both cohorts. Consistent with NAT’s
mechanisms of action, median ALC values for
patients with prior NAT exposure were higher at
baseline vs patients without (2.90 109/l vs
1.97 109/l; Table 3). Although relative percentage
reduction from initial ALC was greater in patients
with prior NAT exposure (decrease of 51.3% at
month 6) than in patients without (decrease of
32.1% at month 6), both reached a similar mean at
month 6 (1.41 109/l vs 1.34 109/l, respectively),
maintained through month 15 (Table 3). Despite the
higher relative reduction, 50% of patients with prior
exposure to NAT remained LLN (0.91 109/l)
during 12 months of DMF treatment.
Similar to these results for ALC, prior NAT expo-
sure influenced the initial decline of CD4þ and
CD8þ counts from baseline to 6 months. Mean
CD4þ T-cell counts in patients without prior NAT
exposure vs those with prior NAT exposure
decreased by 33% vs 46% at month 6 and 37%
vs 52% at month 12, respectively. Likewise, mean
CD8þ T-cell counts in patients without prior NAT
exposure vs those with prior NAT exposure
decreased by 40% vs 57% at month 6 and 46%
vs 65% at month 12, respectively. Although the rel-
ative percentage reductions from initial CD4þ and
CD8þ counts were greater in patients with prior
NAT exposure than in patients without, both
groups demonstrated similar mean CD4þ and
CD8þ counts at month 6 (CD4þ: 0.68109/l vs
0.66109/l, respectively; CD8þ: 0.27109/l vs
0.26109/l, respectively) and at month 12 (CD4þ:
0.60109/l vs 0.62109/l, respectively; CD8þ:
0.23109/l vs 0.24109/l, respectively).
Prior NAT exposure influenced the kinetics of initial
ALC decline, but neither increased nor decreased the
risk of subsequent development of lymphopenia
upon initiation of DMF. In a Cox proportional haz-
ards model adjusted for baseline ALC and age
Table 2. Percentage change in absolute lymphocyte count (ALC), CD4þ count, and CD8þ count.
Mean, 109/la (n¼ 476)
Mean % change
from baselinea
ALC
Baseline 2.23
Month 6 1.36 (1.31–1.40) –39 (–41.1– –37.2)
Month 12 1.24 (1.19–1.29) –44 (–46.6– –42.1)
Month 15 1.20 (1.15–1.25) –46 (–48.3– –43.7)
CD4þ
Baseline 1.06
Month 6 0.67 (0.64–0.69) –37 (–39.3– –35.1)
Month 12 0.61 (0.59–0.64) –42 (–44.5– –39.8)
Month 15 0.60 (0.57–0.62) –44 (–46.2– –41.3)
CD8þ
Baseline 0.50
Month 6 0.27 (0.25–0.38) –47 (–49.0– –44.1)
Month 12 0.24 (0.22–0.25) –53 (–55.5– –49.9)
Month 15 0.23 (0.21–0.24) –55 (–57.6– –51.8)
Mean values at months 6, 12, and 15 were estimated using a repeated-measures mixed-effects model with baseline
ALC, time (log-transformed), and baseline ALCtime interaction effect. Time (log-transformed) was a random effect.
Percentage change was estimated from baseline and the estimated mean change.
aValues in parentheses represent mean 95% confidence intervals.
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Figure 1. Observed (a) absolute lymphocyte count (ALC), (b) CD4þ count, and (c) CD8þ count over time. Change from
baseline ALC was estimated using repeated-measures mixed-effects model analysis.
Table 3. Percentage change in absolute lymphocyte count (ALC) by prior natalizumab (NAT) exposure.
Patients with prior NAT exposure Patients without prior NAT exposure
Mean,109/la
(n¼ 132)b
Mean % change
from baselinec
Mean,109/la
(n¼ 344)
Mean % change
from baselinec
Baseline 2.90 1.97
Month 6 1.41 (1.34–1.48) –51.3 1.34 (1.29–1.39) –32.1
Month 12 1.21 (1.13–1.29) –58.2 1.25 (1.19–1.31) –36.4
Month 15 1.15 (1.07–1.23) –60.4 1.22 (1.16–1.29) –37.8
aValues in parentheses represent mean 95% confidence intervals.
bUp to 180 days prior to dimethyl fumarate (DMF), 132 patients received NAT (two patients received NAT >180 days
prior to DMF and were excluded from the analysis).
cMean values at months 6, 12, and 15 were estimated using a repeated-measures mixed-effects model with baseline
ALC, time (log-transformed), and baseline ALCtime interaction effect. Time (log-transformed) was a random effect.
Percentage change was estimated from baseline and the estimated mean change.
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(50 vs >50 years), the hazard ratio of patients with
and without prior NAT exposure experiencing an ALC
<0.8 109/l while receiving DMF was 1.180 (95%
CI: 0.793 to 1.727; p¼ 0.4048). Similarly, the hazard
ratio for experiencing an ALC<0.5 109/l was 1.247
(95% CI: 0.612 to 2.446; p¼ 0.5304).
Age
At 6 months following initiation of DMF, 25% (18/
72) of patients aged 50 years had an ALC <LLN
and 29% (19/65) of patients aged >50 years had an
ALC <LLN (odds ratio (OR) ¼ 1.24; p ¼ 0.7003;
Table 4). At this time, there was no difference in the
median percentage change from baseline ALC in
patients aged 50 years vs patients aged >50
years (–40.3% vs –45.5%; p ¼ 0.1253). At month
12, 29% (15/51) of patients aged 50 years at base-
line had an ALC <LLN compared with 50% (33/66)
of patients aged >50 years (OR ¼ 2.38; p ¼ 0.0366;
Table 4). Median percentage change from baseline
ALC in patients aged 50 years was smaller than in
patients aged >50 years (40.0% vs 55.7%; p ¼
0.0102) at 12 months.
Results were similar when evaluating change in
ALC. Interpretation of results from both analyses
is limited by the small number of patients with meas-
urements 6 and 12 months after treatment initiation.
Baseline ALC
Baseline ALC correlated with an ALC <LLN at
month 6 (OR¼ 0.51, p¼ 0.0106 with each increase
in baseline ALC of 1.0 109/l), and the percentage
change from baseline at months 6 and 12.
DMF discontinuation and lymphocyte recovery after
DMF discontinuation
In total, 114 (24%) patients discontinued DMF after
an average of 1.3 years of treatment. Forty patients
discontinued for reasons associated with low lym-
phocyte or blood counts (13 of these were aged
50 years and 27 were aged >50 years).
Of 114 patients who discontinued DMF, 29% had1
ALC<0.91 109/l while receiving treatment and>2
months after DMF discontinuation. Among these,
55% (16/29) had ALC values0.91 109/l after dis-
continuation, and mean (standard deviation) time for
receiving DMF treatment before discontinuation of
414 (198) days. While receiving DMF treatment, 23
of 29 patients experienced an ALC <0.8 109/l and
six of 29 experienced an ALC <0.5 109/l (Figure
2). Of 29 patients with1 ALC<0.91 109/l during
DMF treatment and>2 months after DMF discontin-
uation, three initiated NAT and two initiated fingoli-
mod following DMF discontinuation; of 25 patients
who did not initiate NAT or fingolimod after DMF
discontinuation, 12 had ALC values >0.91 109/l.
Safety: adverse events
Since this was a retrospective chart review, adverse
event incidence and severity could not be accurately
determined. Commonly reported infections included
urinary tract infection, respiratory infections, and
varicella zoster. There was no pattern of infection
type among the few patients who experienced a pos-
sible opportunistic or serious infection (n¼ 7 (1%)
in the 6 months prior to DMF treatment; n¼ 38
(8%) during DMF treatment; and n¼ 6 (5%) in
the 6 months after DMF treatment). The most
Table 4. Association between age and absolute lymphocyte count (ALC) <LLN at months 6 and 12.
n Category n/N (%) <LLN ORa Predictor p-valueb
Month 6
Baseline ALC 137 Continuous predictor 0.51 0.0106
Age at baseline, years 137 50 18/72 (25) 1.24 0.7003
>50 19/65 (29)
Month 12
Baseline ALC 117 Continuous predictor 0.78 0.2154
Age at baseline, years 117 50 15/51 (29) 2.38 0.0366
>50 33/66 (50)
LLN: lower limit of normal; OR: odds ratio.
Analysis is restricted to patients with an ALC  0.91 109/l at baseline. Exact logistic regression analysis methods
applied; p-values are from exact conditional tests. For categorical predictor variables, the first category is the reference
category.
aThe OR is the increase in odds of having an event with an increase in baseline ALC of 1.0 109/l.
bThe p-value evaluates the association between ALC <LLN at the timepoint and each predictor variable.
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common infections during DMF treatment were uri-
nary tract infections (n¼ 13), upper respiratory
infections (n¼ 9), lower respiratory infections
(n¼ 5), and varicella zoster (n¼ 4). There were no
significant associations between ALC, CD4þ count,
CD8þ count, and occurrence of possible opportunis-
tic or serious infections for any time period (prior to,
during, or after DMF treatment).
Discussion
The effect of DMF on ALC decline during early
treatment has been assessed in several studies.2,5–10
In integrated analyses of phase 2b/3 extension stud-
ies, mean ALC decreased during the first year, then
plateaued, remaining LLN (0.91 109/l).2 Among
those treated for 6 months (n¼ 2099), ALCs
remained LLN in 84% and 76% of patients after
6 and 12 months, respectively, and were within
normal range at all visits in 61% of patients evalu-
ated. Lowest post-baseline lymphopenia was <LLN
to 0.800 109/l in 9%, <0.800 109/l to 0.500
109/l in 21%, <0.500 109/l to 0.200 109/l in
7%, and <0.200 109/l in <1% of patients overall.
Very rare cases of progressive multifocal leukoence-
phalopathy have occurred in patients treated with
DMF in the clinical trial and post-marketing setting,
predominantly in the context of moderate (0.5
109/l to <0.8 109/l) to severe (<0.5 109/l) lym-
phopenia persisting for 6 months; one case
occurred in a patient with mild lymphopenia.1
Prescribing guidelines vary according to local
labels, but all recommend monitoring lymphocyte
levels and considering discontinuing DMF for
patients with an ALC <0.5 109/l persisting for
6 months.1 Thus, it is important to characterize
ALC profiles in patients with MS during and after
treatment with DMF, especially in the real-world
setting of routine clinical practice.
We found that ALC dynamics over the first year of
DMF treatment were generally consistent with clin-
ical trial observations and other real-world data.2,11
CD4þ and CD8þ T-cell subsets strongly correlated
with ALC; decreases from baseline were more pro-
nounced in the first 6 months of treatment than
months 6–12. A greater reduction in mean ALC
after 12 months of DMF was observed (44%) than
004004–006–008–0001– 002002– 0
Days from DMF discontinuation
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0.0
0.5
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Figure 2. Individual absolute lymphocyte count (ALC) values before and after delayed dimethyl fumarate (DMF)
discontinuation and regression line. The regression line was calculated by locally estimated scatterplot smoothing with
linear interpolation.
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reported by Fox et al. (30%).2 This was likely influ-
enced by the difference in the proportion of patients
who had received prior NAT treatment, known to
increase the number of circulating lymphocytes.12
Patients with prior NAT treatment had on average
a higher baseline ALC compared with patients with-
out prior NAT treatment. Over the course of the
study, there were no differences in mean ALC
values at months 6, 12, and 15 between patients
with prior NAT treatment and those without.
Previous NAT treatment was not found to be a risk
factor for lymphopenia upon subsequent initiation
of DMF. In addition, in a recently published study
of patients with RRMS who switched from NAT to
DMF treatment (STRATEGY), no new major
adverse events were reported compared with what
is already known about the safety profile of DMF.13
Our study demonstrated a more pronounced decline
in CD8þ T cells than in CD4þ T cells. Others have
suggested that such decline is driven by CD8þ
memory cells rather than naive T cells.5,14
Although the clinical relevance of DMF-associated
decline in memory CD8þ T cells remains unclear,
activated CD8þ T cells seem to play a role in the
demyelination of axons in MS lesions.15 In >2500
patients receiving DMF for a median (range) of 5.7
(0.1–8.3) years in the ENDORSE long-term safety
study,16 those with severe prolonged lymphopenia
(2% (n¼ 53)) did not present with an increased inci-
dence of serious infections, herpes infections or with
malignancies and continued treatment after becom-
ing severely lymphopenic for a total median (range)
of 34 (4–81) months before discontinuing.16
REALIZE also assessed the impact of age on the risk
of developing DMF-associated lymphopenia. The
pattern of lymphocyte decline was generally similar
across age groups; however, older age (50 years)
was associated with an increase in median percent-
age decline in ALC at month 12 compared with
younger age (<50 years). This association was not
observed at month 6. Although the incidence of
ALCs <LLN was higher in patients aged 50
years, it should be noted that both younger and
older patients experienced ALCs <LLN
(0.91 109/l). Of note, older age in general is asso-
ciated with immunosenescence, characterized by
decreased levels and functionality of B and T lym-
phocytes.17 The clinical significance of these find-
ings in the context of DMF treatment is unclear; this
study was not powered to determine if there was an
increased risk of prolonged lymphopenia (>6
months duration) in older patients.
Assessment of ALC recovery kinetics and predictors
in patients with lymphopenia who discontinued
DMF treatment was challenging, owing to the low
number of patients who discontinued the study
because of low ALCs (who also had follow-up
ALCs in the absence of other disease-modifying ther-
apies). However, among the small number available
for evaluation, at 2 months after DMF discontinu-
ation ALC values returned to >0.91109/l (<LLN)
in nearly half of patients (12/25). Interestingly, a
recently published article by Chan et al. reports an
analysis of patients from clinical trials and real-
world clinical care, showing that the majority of
patients who discontinued DMF due to lymphope-
nia experienced ALC reconstitution within 2–4
months following DMF discontinuation.18
The strengths of this study include the use of obser-
vational data from routine clinical care and the avail-
ability of baseline ALC assessments; however, there
are limitations with retrospective studies. Data col-
lection was limited to routinely recorded information
and information on laboratory values, as well
as potential confounders, may not have been consis-
tently recorded. Furthermore, although sites were
provided with a list of possible opportunistic
infections and guidance on how to record serious
infections, the decision to record a safety event
as a possible opportunistic or serious infection was
at the discretion of the healthcare provider.
Nevertheless, our results are consistent with previ-
ous studies that have evaluated changes in circulat-
ing immune cells from 6 months to 2 years.9,10,14,19
In summary, our data from real-world clinical prac-
tice support the results of previous clinical trials in
demonstrating that DMF-associated decline in ALC
in the first 12 months of treatment is closely corre-
lated with decline in CD4þ and CD8þ T cells, inde-
pendent of prior NAT treatment. ALC monitoring
continues to be an effective strategy to identify
patients who may be at risk of prolonged lymphope-
nia over the first year of DMF treatment, irrespective
of age. These results may help guide clinicians in
managing patients at risk of lymphopenia during
DMF treatment.
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